{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:12:38Z","timestamp":1791655958491,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10072-026-09078-1","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:45:50Z","timestamp":1778564750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of CGRP monoclonal antibodies for cluster headache: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5653-1931","authenticated-orcid":false,"given":"Muneeb Ahmad","family":"Muneer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areesha","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poorvikha","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debankur","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diya","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malavika","family":"Rudrakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2499-4874","authenticated-orcid":false,"given":"Amogh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8332-6391","authenticated-orcid":false,"given":"Ranjana","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Ezzeldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"9078_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1456517","volume":"15","author":"XH Xu","year":"2024","unstructured":"Xu XH, Li YM, Ren LN, Xu XF, Dai YL, Jin CQ, Yang RR (2024) Cluster headache: understandings of current knowledge and directions for whole process management. Front Neurol 15:1456517. https:\/\/doi.org\/10.3389\/fneur.2024.1456517","journal-title":"Front Neurol"},{"issue":"10","key":"9078_CR2","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamaneurol.2018.1675","volume":"75","author":"ALH Vollesen","year":"2018","unstructured":"Vollesen ALH, Snoer A, Beske RP, Guo S, Hoffmann J, Jensen RH, Ashina M (2018) Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurol 75(10):1187\u20131197. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1675","journal-title":"JAMA Neurol"},{"issue":"9","key":"9078_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231201577","volume":"43","author":"SA Kim","year":"2023","unstructured":"Kim SA, Choi SY, Youn MS, Pozo-Rosich P, Lee MJ (2023) Epidemiology, burden and clinical spectrum of cluster headache: a global update. Cephalalgia 43(9):3331024231201577. https:\/\/doi.org\/10.1177\/03331024231201577","journal-title":"Cephalalgia"},{"key":"9078_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2024.1373528","volume":"5","author":"D San-Juan","year":"2024","unstructured":"San-Juan D, Velez-Jimenez K, Hoffmann J, Mart\u00ednez-Mayorga AP, Melo-Carrillo A, Rodr\u00edguez-Leyva I, Garc\u00eda S, Collado-Ortiz M\u00c1, Chiquete E, Gudi\u00f1o-Castelazo M, Ju\u00e1rez-Jimenez H, Mart\u00ednez-Gurrola M, Marfil A, Nader-Kawachi JA, Uribe-Jaimes PD, Dar\u00edo-Vargas R, Villareal-Careaga J (2024) Cluster headache: an update on clinical features, epidemiology, pathophysiology, diagnosis, and treatment. Front Pain Res 5:1373528. https:\/\/doi.org\/10.3389\/fpain.2024.1373528","journal-title":"Front Pain Res"},{"issue":"1","key":"9078_CR5","first-page":"24","volume":"105","author":"OO Malu","year":"2022","unstructured":"Malu OO, Bailey J, Hawks MK (2022) Cluster headache: rapid evidence review. Am Fam Physician 105(1):24\u201332","journal-title":"Am Fam Physician"},{"issue":"1","key":"9078_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40122-024-00674-7","volume":"14","author":"DB de Freitas","year":"2025","unstructured":"de Freitas DB, Robinson CL, Villar-Martinez MD, Ashina S, Goadsby PJ (2025) Current and novel therapies for cluster headache: a narrative review. Pain Ther 14(1):1\u201319. https:\/\/doi.org\/10.1007\/s40122-024-00674-7","journal-title":"Pain Ther"},{"issue":"Supplement","key":"9078_CR7","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.4103\/0028-3886.315983","volume":"69","author":"S Cheema","year":"2021","unstructured":"Cheema S, Matharu M (2021) Cluster headache: what\u2019s new? Neurol India 69(Supplement):S124\u2013S134. https:\/\/doi.org\/10.4103\/0028-3886.315983","journal-title":"Neurol India"},{"key":"9078_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2147\/NSS.S278088","volume":"13","author":"M Barloese","year":"2021","unstructured":"Barloese M (2021) Current understanding of the chronobiology of cluster headache and the role of sleep in its management. Nat Sci Sleep 13:153\u2013162. https:\/\/doi.org\/10.2147\/NSS.S278088","journal-title":"Nat Sci Sleep"},{"issue":"1","key":"9078_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-021-01658-z","volume":"82","author":"HC Diener","year":"2022","unstructured":"Diener HC, May A (2022) Drug treatment of cluster headache. Drugs 82(1):33\u201342. https:\/\/doi.org\/10.1007\/s40265-021-01658-z","journal-title":"Drugs"},{"issue":"3","key":"9078_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43(3):3331024231152169. https:\/\/doi.org\/10.1177\/03331024231152169","journal-title":"Cephalalgia"},{"key":"9078_CR11","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2147\/JPR.S222604","volume":"13","author":"L Pellesi","year":"2020","unstructured":"Pellesi L, De Icco R, Al-Karagholi MA, Ashina M (2020) Reducing episodic cluster headaches: focus on Galcanezumab. J Pain Res 13:1591\u20131599. https:\/\/doi.org\/10.2147\/JPR.S222604","journal-title":"J Pain Res"},{"issue":"1","key":"9078_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00716-w","volume":"27","author":"H Sevivas","year":"2022","unstructured":"Sevivas H, Fresco P (2022) Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res 27(1):86. https:\/\/doi.org\/10.1186\/s40001-022-00716-w","journal-title":"Eur J Med Res"},{"issue":"2","key":"9078_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","volume":"381","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, Zhou C, Dowsett SA, Aurora SK, Ahn AH, Yang JY, Conley RR, Martinez JM (2019) Trial of Galcanezumab in prevention of episodic cluster headache. N Engl J Med 381(2):132\u2013141. https:\/\/doi.org\/10.1056\/NEJMoa1813440","journal-title":"N Engl J Med"},{"key":"9078_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"9078_CR15","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) (2024) Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane. Available from www.training.cochrane.org\/handbook"},{"issue":"9","key":"9078_CR16","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0333102420905321","volume":"40","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, Zhou C, Aurora SK, Yang JY, Conley RR, Oakes T (2020) Phase 3 randomized, placebo-controlled study of Galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia 40(9):935\u2013948. https:\/\/doi.org\/10.1177\/0333102420905321","journal-title":"Cephalalgia"},{"key":"9078_CR17","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.2147\/JPR.S305066","volume":"14","author":"JS Andrews","year":"2021","unstructured":"Andrews JS, Kudrow D, Rettiganti M, Oakes T, Bardos JN, Wenzel R, Kuruppu DK, Gaul C, Martinez JM (2021) Impact of Galcanezumab on total pain burden: a post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study in patients with episodic cluster headache. J Pain Res 14:2059\u20132070. https:\/\/doi.org\/10.2147\/JPR.S305066","journal-title":"J Pain Res"},{"key":"9078_CR18","unstructured":"Teva Branded Pharmaceutical Products R&D, Inc (2017) A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH). ClinicalTrials.gov. Report No.: NCT02964338. https:\/\/clinicaltrials.gov\/study\/NCT02964338"},{"key":"9078_CR19","unstructured":"H.\u202fLundbeck A\/S (2021) Teva Branded Pharmaceutical Products R&D, Inc. Efficacy and safety of eptinezumab in participants with episodic cluster headache (ALLEVIATE). ClinicalTrials.gov. Report No.: NCT04688775. https:\/\/clinicaltrials.gov\/study\/NCT04688775"},{"key":"9078_CR20","unstructured":"Teva Branded Pharmaceutical Products, R&D Inc. (2017) A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous\/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Epidosic Cluster Headache. ClinicalTrials.gov. Report No.: NCT02945046. https:\/\/clinicaltrials.gov\/study\/NCT02945046"},{"issue":"3","key":"9078_CR21","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","volume":"19","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, DePoy EMG, Silberstein SD (2022) The arrival of anti-CGRP monoclonal antibodies in migraine. Neurotherapeutics 19(3):922\u2013930. https:\/\/doi.org\/10.1007\/s13311-022-01230-x","journal-title":"Neurotherapeutics"},{"issue":"3","key":"9078_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030245","volume":"14","author":"P Gklinos","year":"2021","unstructured":"Gklinos P, Mitsikostas DD (2021) The role of Galcanezumab in migraine prevention: existing data and future directions. Pharmaceuticals (Basel) 14(3):245. https:\/\/doi.org\/10.3390\/ph14030245","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"9078_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01472-2","volume":"23","author":"X Wang","year":"2022","unstructured":"Wang X, Wen D, He Q, You C, Ma L (2022) Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. J Headache Pain 23(1):105. https:\/\/doi.org\/10.1186\/s10194-022-01472-2","journal-title":"J Headache Pain"},{"issue":"9488","key":"9078_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0140-6736(05)67217-0","volume":"366","author":"A May","year":"2005","unstructured":"May A (2005) Cluster headache: pathogenesis, diagnosis, and management. Lancet 366(9488):843\u2013855. https:\/\/doi.org\/10.1016\/S0140-6736(05)67217-0","journal-title":"Lancet"},{"issue":"1","key":"9078_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01660-8","volume":"24","author":"NLT Lund","year":"2023","unstructured":"Lund NLT, Petersen AS, Fronczek R, Tfelt-Hansen J, Belin AC, Meisingset T, Tronvik E, Steinberg A, Gaul C, Jensen RH (2023) Current treatment options for cluster headache: limitations and the unmet need for better and specific treatments-a consensus article. J Headache Pain 24(1):121. https:\/\/doi.org\/10.1186\/s10194-023-01660-8","journal-title":"J Headache Pain"},{"issue":"1","key":"9078_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48\u201356. https:\/\/doi.org\/10.1002\/ana.410330109","journal-title":"Ann Neurol"},{"issue":"3","key":"9078_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231226181","volume":"44","author":"R Lamas P\u00e9rez","year":"2024","unstructured":"Lamas P\u00e9rez R, Mill\u00e1n-V\u00e1zquez M, Gonz\u00e1lez-Oria C (2024) Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: observational prospective study. Cephalalgia 44(3):3331024231226181. https:\/\/doi.org\/10.1177\/03331024231226181","journal-title":"Cephalalgia"},{"issue":"11\u201312","key":"9078_CR28","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/03331024221103509","volume":"42","author":"R Riesenberg","year":"2022","unstructured":"Riesenberg R, Gaul C, Stroud CE, Dong Y, Bangs ME, Wenzel R, Martinez JM, Oakes TM (2022) Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache. Cephalalgia 42(11\u201312):1225\u20131235. https:\/\/doi.org\/10.1177\/03331024221103509","journal-title":"Cephalalgia"},{"issue":"3","key":"9078_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3988\/jcn.2023.0311","volume":"20","author":"MS Youn","year":"2024","unstructured":"Youn MS, Kim N, Lee MJ, Kim M (2024) Treatment outcome after switching from Galcanezumab to Fremanezumab in patients with migraine. J Clin Neurol 20(3):300\u2013305. https:\/\/doi.org\/10.3988\/jcn.2023.0311","journal-title":"J Clin Neurol"},{"issue":"11","key":"9078_CR30","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/1440-1681.13700","volume":"49","author":"YMT Siahaan","year":"2022","unstructured":"Siahaan YMT, Hartoyo V, Hariyanto TI (2022) Efficacy and safety of eptinezumab as preventive treatment for episodic\/chronic migraine: a systematic review and meta-analysis. Clin Exp Pharmacol Physiol 49(11):1156\u20131168. https:\/\/doi.org\/10.1111\/1440-1681.13700","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"5","key":"9078_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1474-4422(25)00065-1","volume":"24","author":"C Tassorelli","year":"2025","unstructured":"Tassorelli C, Jensen RH, Goadsby PJ, Charles AC, Tepper SJ, Snoer AH, Josiassen MK, Linander CB, Ettrup A, Sperling B, Boneva N (2025) Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial. Lancet Neurol 24(5):429\u2013440. https:\/\/doi.org\/10.1016\/S1474-4422(25)00065-1","journal-title":"Lancet Neurol"},{"issue":"10","key":"9078_CR32","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/0333102419840780","volume":"39","author":"W Kielbasa","year":"2019","unstructured":"Kielbasa W, Helton DL (2019) A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia 39(10):1284\u20131297. https:\/\/doi.org\/10.1177\/0333102419840780","journal-title":"Cephalalgia"},{"issue":"2","key":"9078_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","volume":"24","author":"AS Wattiez","year":"2020","unstructured":"Wattiez AS, Sowers LP, Russo AF (2020) Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets 24(2):91\u2013100. https:\/\/doi.org\/10.1080\/14728222.2020.1724285","journal-title":"Expert Opin Ther Targets"},{"key":"9078_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40122-024-00674-7","volume":"14","author":"B de Freitas Dias","year":"2025","unstructured":"de Freitas Dias B, Robinson CL, Villar-Martinez MD et al (2025) Current and novel therapies for cluster headache: a narrative review. Pain Ther 14:1\u201319. https:\/\/doi.org\/10.1007\/s40122-024-00674-7","journal-title":"Pain Ther"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09078-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09078-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09078-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:05:32Z","timestamp":1780988732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09078-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["9078"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09078-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As our research is secondary in nature and based on published data, the requirement for informed consent and institutional ethical board approval is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no financial interests relevant to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no non-financial interests relevant to this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable, as this study does not report a clinical trial.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research registry number"}},{"value":"Generative AI tools, including Paperpal and ChatGPT-4o, were utilized solely for language, grammar, and stylistic refinement. These tools had no role in the conceptualization, data analysis, interpretation of results, or substantive content development of this manuscript. All intellectual contributions, data analysis, and scientific interpretations remain the sole work of the authors. The final content was critically reviewed and edited to ensure accuracy and originality. The authors take full responsibility for the accuracy, originality, and integrity of the work presented.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI use"}}],"article-number":"488"}}